{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:19:56Z","timestamp":1792657196321,"version":"4.5.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2009,2,1]],"date-time":"2009-02-01T00:00:00Z","timestamp":1233446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2009,2]]},"DOI":"10.1038\/ncprheum0987","type":"journal-article","created":{"date-parts":[[2009,2,2]],"date-time":"2009-02-02T06:53:36Z","timestamp":1233557616000},"page":"83-91","source":"Crossref","is-referenced-by-count":106,"title":["New insights into the pathogenesis and genetics of psoriatic arthritis"],"prefix":"10.1038","volume":"5","author":[{"given":"Kristine E","family":"Nograles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D","family":"Brasington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M","family":"Bowcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFncprheum0987_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jaad.2004.07.045","volume":"52","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM et al. (2005) The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 52: 23\u201326","journal-title":"J Am Acad Dermatol"},{"key":"BFncprheum0987_CR2","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.jaad.2008.02.039","volume":"58","author":"A Menter","year":"2008","unstructured":"Menter A et al. (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 58: 826\u2013850","journal-title":"J Am Acad Dermatol"},{"key":"BFncprheum0987_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/00015550252948130","volume":"82","author":"H Zachariae","year":"2002","unstructured":"Zachariae H et al. (2002) Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. Acta Derm Venereol 82: 108\u2013113","journal-title":"Acta Derm Venereol"},{"key":"BFncprheum0987_CR4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/rheumatology\/ken090","volume":"47","author":"LS Tam","year":"2008","unstructured":"Tam LS et al. (2008) Cardiovascular risk profile of patients with psoriatic arthritis compared to controls\u2014the role of inflammation. Rheumatology (Oxford) 47: 718\u2013723","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0987_CR5","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann AL et al. (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55: 829\u2013835","journal-title":"J Am Acad Dermatol"},{"key":"BFncprheum0987_CR6","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/S0198-8859(03)00162-9","volume":"64","author":"DD Gladman","year":"2003","unstructured":"Gladman DD et al. (2003) HLA is a candidate region for psoriatic arthritis: evidence for excessive HLA sharing in sibling pairs. Hum Immunol 64: 887\u2013889","journal-title":"Hum Immunol"},{"key":"BFncprheum0987_CR7","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/hmg\/7.10.1537","volume":"7","author":"J Bhalerao","year":"1998","unstructured":"Bhalerao J and Bowcock AM (1998) The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet 7: 1537\u20131545","journal-title":"Hum Mol Genet"},{"key":"BFncprheum0987_CR8","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1093\/rheumatology\/keh589","volume":"44","author":"A Myers","year":"2005","unstructured":"Myers A et al. (2005) Recurrence risk for psoriasis and psoriatic arthritis within sibships. Rheumatology (Oxford) 44: 773\u2013776","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 2","key":"BFncprheum0987_CR9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/ard.2004.030775","volume":"64","author":"P Rahman","year":"2005","unstructured":"Rahman P and Elder JT (2005) Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis 64 (Suppl 2): 37\u201339","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0987_CR10","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0140-6736(07)61128-3","volume":"370","author":"CE Griffiths","year":"2007","unstructured":"Griffiths CE and Barker JN (2007) Pathogenesis and clinical features of psoriasis. Lancet 370: 263\u2013271","journal-title":"Lancet"},{"key":"BFncprheum0987_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1002\/art.21079","volume":"53","author":"C Palazzi","year":"2005","unstructured":"Palazzi C et al. (2005) Hepatitis C virus infection in psoriatic arthritis. Arthritis Rheum 53: 223\u2013225","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0987_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll JM and Wright V (1973) Psoriatic arthritis. Semin Arthritis Rheum 3: 55\u201378","journal-title":"Semin Arthritis Rheum"},{"key":"BFncprheum0987_CR13","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W et al. (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54: 2665\u20132673","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"BFncprheum0987_CR14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/ard.2004.032482","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman DD et al. (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64 (Suppl 2): 14\u201317","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0987_CR15","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.clindermatol.2006.07.006","volume":"24","author":"WA Myers","year":"2006","unstructured":"Myers WA et al. (2006) Psoriasis and psoriatic arthritis: clinical features and disease mechanisms. Clin Dermatol 24: 438\u2013447","journal-title":"Clin Dermatol"},{"issue":"Suppl 2","key":"BFncprheum0987_CR16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/ard.2004.034264","volume":"64","author":"D McGonagle","year":"2005","unstructured":"McGonagle D (2005) Imaging the joint and enthesis: insights into pathogenesis of psoriatic arthritis. Ann Rheum Dis 64 (Suppl 2): 58\u201360","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"BFncprheum0987_CR17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard.2004.030783","volume":"64","author":"P Nash","year":"2005","unstructured":"Nash P and Clegg DO (2005) Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 64 (Suppl 2): 74\u201377","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0987_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A et al. (2008) Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 58: 851\u2013864","journal-title":"J Am Acad Dermatol"},{"key":"BFncprheum0987_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.clindermatol.2007.11.006","volume":"26","author":"RB Warren","year":"2008","unstructured":"Warren RB and Griffiths CE (2008) Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clin Dermatol 26: 438\u2013447","journal-title":"Clin Dermatol"},{"key":"BFncprheum0987_CR20","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/ar419","volume":"4","author":"ES Chan","year":"2002","unstructured":"Chan ES and Cronstein BN (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4: 266\u2013273","journal-title":"Arthritis Res"},{"key":"BFncprheum0987_CR21","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/art.21870","volume":"54","author":"PJ Mease","year":"2006","unstructured":"Mease PJ (2006) Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 54: 1638\u20131645","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0987_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1365-2133.2006.07344.x","volume":"155","author":"L Dubertret","year":"2006","unstructured":"Dubertret L et al. (2006) Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 155: 170\u2013181","journal-title":"Br J Dermatol"},{"key":"BFncprheum0987_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2310\/7750.2007.00006","volume":"11","author":"KA Papp","year":"2007","unstructured":"Papp KA et al. (2007) Efalizumab for the treatment of psoriatic arthritis. J Cutan Med Surg 11: 57\u201366","journal-title":"J Cutan Med Surg"},{"key":"BFncprheum0987_CR24","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1080\/09546630600967406","volume":"17","author":"WA Myers","year":"2006","unstructured":"Myers WA et al. (2006) New-onset, debilitating arthritis in psoriasis patients receiving efalizumab. J Dermatolog Treat 17: 353\u2013354","journal-title":"J Dermatolog Treat"},{"issue":"Suppl 2","key":"BFncprheum0987_CR25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1136\/ard.2004.034157","volume":"64","author":"PJ Mease","year":"2005","unstructured":"Mease PJ and Antoni CE (2005) Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 64 (Suppl 2): 78\u201382","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0987_CR26","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1517\/14728222.12.9.1085","volume":"12","author":"F Fantuzzi","year":"2008","unstructured":"Fantuzzi F et al. (2008) Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 12: 1085\u20131096","journal-title":"Expert Opin Ther Targets"},{"key":"BFncprheum0987_CR27","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1084\/jem.20071094","volume":"204","author":"LC Zaba","year":"2007","unstructured":"Zaba LC et al. (2007) Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 204: 3183\u20133194","journal-title":"J Exp Med"},{"key":"BFncprheum0987_CR28","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/art.23835","volume":"59","author":"AN Collamer","year":"2008","unstructured":"Collamer AN et al. (2008) Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 59: 996\u20131001","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0987_CR29","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","volume":"371","author":"CL Leonardi","year":"2008","unstructured":"Leonardi CL et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665\u20131674","journal-title":"Lancet"},{"key":"BFncprheum0987_CR30","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ncprheum0670","volume":"3","author":"C Ritchlin","year":"2007","unstructured":"Ritchlin C (2007) Psoriatic disease\u2014from skin to bone. Nat Clin Pract Rheumatol 3: 698\u2013706","journal-title":"Nat Clin Pract Rheumatol"},{"key":"BFncprheum0987_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0198-8859(98)00123-2","volume":"60","author":"DD Gladman","year":"1999","unstructured":"Gladman DD et al. (1999) HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol 60: 259\u2013261","journal-title":"Hum Immunol"},{"key":"BFncprheum0987_CR32","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0923-1811(02)00072-5","volume":"30","author":"Y Tsunemi","year":"2002","unstructured":"Tsunemi Y et al. (2002) Interleukin-12 p40 gene (IL12B) 3\u2032-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris. J Dermatol Sci 30: 161\u2013166","journal-title":"J Dermatol Sci"},{"key":"BFncprheum0987_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1086\/503821","volume":"78","author":"RP Nair","year":"2006","unstructured":"Nair RP et al. (2006) Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet 78: 827\u2013851","journal-title":"Am J Hum Genet"},{"key":"BFncprheum0987_CR34","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1007\/s00439-005-0048-2","volume":"118","author":"C Helms","year":"2005","unstructured":"Helms C et al. (2005) Localization of PSORS1 to a haplotype block harboring HLA-C and distinct from corneodesmosin and HCR. Hum Genet 118: 466\u2013476","journal-title":"Hum Genet"},{"key":"BFncprheum0987_CR35","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1086\/342289","volume":"71","author":"CD Veal","year":"2002","unstructured":"Veal CD et al. (2002) Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet 71: 554\u2013564","journal-title":"Am J Hum Genet"},{"key":"BFncprheum0987_CR36","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/sj.jid.5700357","volume":"126","author":"JT Elder","year":"2006","unstructured":"Elder JT (2006) PSORS1: linking genetics and immunology. J Invest Dermatol 126: 1205\u20131206","journal-title":"J Invest Dermatol"},{"key":"BFncprheum0987_CR37","doi-asserted-by":"publisher","first-page":"e1000041","DOI":"10.1371\/journal.pgen.1000041","volume":"4","author":"Y Liu","year":"2008","unstructured":"Liu Y et al. (2008) A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 4: e1000041","journal-title":"PLoS Genet"},{"key":"BFncprheum0987_CR38","first-page":"4","volume":"30","author":"DD Gladman","year":"2003","unstructured":"Gladman DD and Farewell VT (2003) HLA studies in psoriatic arthritis: current situation and future needs. J Rheumatol 30: 4\u20136","journal-title":"J Rheumatol"},{"key":"BFncprheum0987_CR39","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s11926-005-0041-8","volume":"7","author":"E Korendowych","year":"2005","unstructured":"Korendowych E and McHugh N (2005) Genetic factors in psoriatic arthritis. Curr Rheumatol Rep 7: 306\u2013312","journal-title":"Curr Rheumatol Rep"},{"key":"BFncprheum0987_CR40","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/ard.2006.064972","volume":"66","author":"PY Ho","year":"2007","unstructured":"Ho PY et al. (2007) HLA-Cw6 and HLA-DRB1*07 together are associated with less severe joint disease in psoriatic arthritis. Ann Rheum Dis 66: 807\u2013811","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0987_CR41","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/art.22590","volume":"56","author":"K Reich","year":"2007","unstructured":"Reich K et al. (2007) TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-857 independent of the PSORS1 risk allele. Arthritis Rheum 56: 2056\u20132064","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0987_CR42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.humimm.2005.04.005","volume":"66","author":"F Williams","year":"2005","unstructured":"Williams F et al. (2005) Activating killer cell immunoglobulin-like receptor gene KIR2DS1 is associated with psoriatic arthritis. Hum Immunol 66: 836\u2013841","journal-title":"Hum Immunol"},{"key":"BFncprheum0987_CR43","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.4049\/jimmunol.173.7.4273","volume":"173","author":"GW Nelson","year":"2004","unstructured":"Nelson GW et al. (2004) Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection\/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 173: 4273\u20134276","journal-title":"J Immunol"},{"key":"BFncprheum0987_CR44","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1097\/QAD.0b013e3282ffde7e","volume":"22","author":"S Boulet","year":"2008","unstructured":"Boulet S et al. (2008) A combined genotype of KIR3DL1 high expressing alleles and HLA-B*57 is associated with a reduced risk of HIV infection. Aids 22: 1487\u20131491","journal-title":"Aids"},{"key":"BFncprheum0987_CR45","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.coi.2005.07.012","volume":"17","author":"MP Martin","year":"2005","unstructured":"Martin MP and Carrington M (2005) Immunogenetics of viral infections. Curr Opin Immunol 17: 510\u2013516","journal-title":"Curr Opin Immunol"},{"key":"BFncprheum0987_CR46","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1086\/511051","volume":"80","author":"M Cargill","year":"2007","unstructured":"Cargill M et al. (2007) A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 80: 273\u2013290","journal-title":"Am J Hum Genet"},{"key":"BFncprheum0987_CR47","doi-asserted-by":"crossref","unstructured":"Huffmeier U et al. (2008) Genetic variants of the IL-23R pathway: association with psoriatic arthritis and psoriasis vulgaris, but no specific risk factor for arthritis. J Invest Dermatol [10.1038\/jid.2008.233]","DOI":"10.1038\/jid.2008.233"},{"key":"BFncprheum0987_CR48","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1126\/science.1135245","volume":"314","author":"RH Duerr","year":"2006","unstructured":"Duerr RH et al. (2006) A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 314: 1461\u20131463","journal-title":"Science"},{"key":"BFncprheum0987_CR49","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1038\/ng.2007.17","volume":"39","author":"PR Burton","year":"2007","unstructured":"Burton PR et al. (2007) Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 39: 1329\u20131337","journal-title":"Nat Genet"},{"key":"BFncprheum0987_CR50","unstructured":"Nair RP et al.: Genome-wide scan reveals association of psoriasis with IL-23 and NF-\u03baB pathways. Nat Genet (in press)"},{"key":"BFncprheum0987_CR51","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1084\/jem.20030451","volume":"199","author":"E Lee","year":"2004","unstructured":"Lee E et al. (2004) Increased expression of interleukin-23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199: 125\u2013130","journal-title":"J Exp Med"},{"key":"BFncprheum0987_CR52","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/kel306","volume":"46","author":"P Szodoray","year":"2007","unstructured":"Szodoray P et al. (2007) Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford) 46: 417\u2013425","journal-title":"Rheumatology (Oxford)"},{"key":"BFncprheum0987_CR53","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.immuni.2008.03.001","volume":"28","author":"MJ McGeachy","year":"2008","unstructured":"McGeachy MJ and Cua DJ (2008) Th17 cell differentiation: the long and winding road. Immunity 28: 445\u2013453","journal-title":"Immunity"},{"key":"BFncprheum0987_CR54","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s10875-008-9239-7","volume":"28","author":"A Awasthi","year":"2008","unstructured":"Awasthi A et al. (2008) Interplay between effector Th17 and regulatory T cells. J Clin Immunol 28: 660\u2013670","journal-title":"J Clin Immunol"},{"key":"BFncprheum0987_CR55","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","volume":"128","author":"MA Lowes","year":"2008","unstructured":"Lowes MA et al. (2008) Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 128: 1207\u20131211","journal-title":"J Invest Dermatol"},{"key":"BFncprheum0987_CR56","first-page":"1092","volume":"159","author":"K Nograles","year":"2008","unstructured":"Nograles K (2008) Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159: 1092\u2013102","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"BFncprheum0987_CR57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard.2004.031120","volume":"64","author":"JG Krueger","year":"2005","unstructured":"Krueger JG and Bowcock A (2005) Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 64 (Suppl 2): 30\u201336","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0987_CR58","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/art.1780360705","volume":"36","author":"D Veale","year":"1993","unstructured":"Veale D et al. (1993) Reduced synovial membrane macrophage numbers, elam-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum 36: 893\u2013900","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0987_CR59","first-page":"1117","volume":"26","author":"P Costello","year":"1999","unstructured":"Costello P et al. (1999) Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol 26: 1117\u20131124","journal-title":"J Rheumatol"},{"key":"BFncprheum0987_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/path.2153","volume":"212","author":"S Colucci","year":"2007","unstructured":"Colucci S et al. (2007) Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol 212: 47\u201355","journal-title":"J Pathol"},{"key":"BFncprheum0987_CR61","doi-asserted-by":"publisher","first-page":"R96","DOI":"10.1186\/ar2297","volume":"9","author":"T Yago","year":"2007","unstructured":"Yago T et al. (2007) IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther 9: R96","journal-title":"Arthritis Res Ther"},{"issue":"Suppl","key":"BFncprheum0987_CR62","first-page":"S577","volume":"58","author":"A Gottlieb","year":"2008","unstructured":"Gottlieb A (2008) Phase 2 study of ustekinumab, a human IL-12\/23 monoclonal antibody, in psoriatic arthritis: ACR criteria component score response through week 36 [abstract #1102]. Arthritis Rheum 58 (Suppl): S577","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0987_CR63","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/ng2058","volume":"39","author":"DA van Heel","year":"2007","unstructured":"van Heel DA et al. (2007) A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 39: 827\u2013829","journal-title":"Nat Genet"},{"key":"BFncprheum0987_CR64","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ng2068","volume":"39","author":"JA Todd","year":"2007","unstructured":"Todd JA et al. (2007) Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 39: 857\u2013864","journal-title":"Nat Genet"},{"key":"BFncprheum0987_CR65","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1086\/522037","volume":"81","author":"A Zhernakova","year":"2007","unstructured":"Zhernakova A et al. (2007) Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 81: 1284\u20131288","journal-title":"Am J Hum Genet"},{"key":"BFncprheum0987_CR66","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1136\/ard.2007.075424","volume":"67","author":"AH Sawalha","year":"2008","unstructured":"Sawalha AH et al. (2008) Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 67: 458\u2013461","journal-title":"Ann Rheum Dis"},{"key":"BFncprheum0987_CR67","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1067\/mjd.2000.106515","volume":"43","author":"JG Krueger","year":"2000","unstructured":"Krueger JG et al. (2000) Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis. J Am Acad Dermatol 43: 448\u2013458","journal-title":"J Am Acad Dermatol"},{"key":"BFncprheum0987_CR68","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1189\/jlb.0503228","volume":"74","author":"DA Horwitz","year":"2003","unstructured":"Horwitz DA et al. (2003) The role of the combination of IL-2 and TGF-\u03b2 or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol 74: 471\u2013478","journal-title":"J Leukoc Biol"},{"key":"BFncprheum0987_CR69","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1189\/jlb.72.5.856","volume":"72","author":"J Parrish-Novak","year":"2002","unstructured":"Parrish-Novak J et al. (2002) Interleukin-21 and the IL-21 receptor: novel effectors of NK and T cell responses. J Leukoc Biol 72: 856\u2013863","journal-title":"J Leukoc Biol"},{"key":"BFncprheum0987_CR70","doi-asserted-by":"publisher","first-page":"34605","DOI":"10.1074\/jbc.M705100200","volume":"282","author":"L Wei","year":"2007","unstructured":"Wei L et al. (2007) IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 282: 34605\u201334610","journal-title":"J Biol Chem"},{"key":"BFncprheum0987_CR71","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1038\/ni1488","volume":"8","author":"L Zhou","year":"2007","unstructured":"Zhou L et al. (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 8: 967\u2013974","journal-title":"Nat Immunol"},{"key":"BFncprheum0987_CR72","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nature06878","volume":"453","author":"L Zhou","year":"2008","unstructured":"Zhou L et al. (2008) TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing ROR\u03b3t function. Nature 453: 236\u2013240","journal-title":"Nature"},{"key":"BFncprheum0987_CR73","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2008-01-133967","volume":"112","author":"HJ Koenen","year":"2008","unstructured":"Koenen HJ et al. (2008) Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112: 2340\u20132352","journal-title":"Blood"},{"key":"BFncprheum0987_CR74","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/art.23138","volume":"56","author":"MM Zaiss","year":"2007","unstructured":"Zaiss MM et al. (2007) TREG cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum 56: 4104\u20134112","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0987_CR75","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/nri1500","volume":"4","author":"W Cookson","year":"2004","unstructured":"Cookson W (2004) The immunogenetics of asthma and eczema: a new focus on the epithelium. Nat Rev Immunol 4: 978\u2013988","journal-title":"Nat Rev Immunol"},{"key":"BFncprheum0987_CR76","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1093\/hmg\/ddn196","volume":"17","author":"Y Li","year":"2008","unstructured":"Li Y et al. (2008) The 5q31 variants associated with psoriasis and Crohn's disease are distinct. Hum Mol Genet 17: 2978\u20132985","journal-title":"Hum Mol Genet"},{"key":"BFncprheum0987_CR77","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1002\/art.21393","volume":"52","author":"P Ho","year":"2005","unstructured":"Ho P et al. (2005) Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 52: 3596\u20133602","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0987_CR78","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.4049\/jimmunol.163.10.5383","volume":"163","author":"A Finnegan","year":"1999","unstructured":"Finnegan A et al. (1999) Proteoglycan (aggrecan)-induced arthritis in BALB\/c mice is a Th1-type disease regulated by Th2 cytokines. J Immunol 163: 5383\u20135390","journal-title":"J Immunol"},{"key":"BFncprheum0987_CR79","doi-asserted-by":"publisher","first-page":"984","DOI":"10.4049\/jimmunol.179.2.984","volume":"179","author":"C Albanesi","year":"2007","unstructured":"Albanesi C et al. (2007) IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 179: 984\u2013992","journal-title":"J Immunol"},{"key":"BFncprheum0987_CR80","doi-asserted-by":"publisher","first-page":"6107","DOI":"10.4049\/jimmunol.175.9.6107","volume":"175","author":"A Skapenko","year":"2005","unstructured":"Skapenko A et al. (2005) The IL-4 receptor alpha-chain-binding cytokines, IL-4 and IL-13, induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25\u2212CD4+ precursors. J Immunol 175: 6107\u20136116","journal-title":"J Immunol"},{"key":"BFncprheum0987_CR81","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/ng.202","volume":"40","author":"SL Musone","year":"2008","unstructured":"Musone SL et al. (2008) Multiple polymorphisms in the TNFAIP3 region are independently associated with systemic lupus erythematosus. Nat Genet 40: 1062\u20131064","journal-title":"Nat Genet"},{"key":"BFncprheum0987_CR82","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/ng.2007.32","volume":"39","author":"W Thomson","year":"2007","unstructured":"Thomson W et al. (2007) Rheumatoid arthritis association at 6q23. Nat Genet 39: 1431\u20131433","journal-title":"Nat Genet"},{"key":"BFncprheum0987_CR83","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/ng.2007.27","volume":"39","author":"RM Plenge","year":"2007","unstructured":"Plenge RM et al. (2007) Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 39: 1477\u20131482","journal-title":"Nat Genet"},{"key":"BFncprheum0987_CR84","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1002\/art.21928","volume":"54","author":"P Rahman","year":"2006","unstructured":"Rahman P et al. (2006) Association between the interleukin-1 family gene cluster and psoriatic arthritis. Arthritis Rheum 54: 2321\u20132325","journal-title":"Arthritis Rheum"},{"key":"BFncprheum0987_CR85","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/jcp.44.8.664","volume":"44","author":"NA Athanasou","year":"1991","unstructured":"Athanasou NA et al. (1991) Use of monoclonal antibodies to recognise osteoclasts in routinely processed bone biopsy specimens. J Clin Pathol 44: 664\u2013666","journal-title":"J Clin Pathol"},{"key":"BFncprheum0987_CR86","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/sj.jid.5700310","volume":"126","author":"F Wang","year":"2006","unstructured":"Wang F et al. (2006) Prominent production of IL-20 by CD68+\/CD11c+ myeloid-derived cells in psoriasis: Gene regulation and cellular effects. J Invest Dermatol 126: 1590\u20131609","journal-title":"J Invest Dermatol"},{"key":"BFncprheum0987_CR87","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1189\/jlb.1006610","volume":"81","author":"S Nakae","year":"2007","unstructured":"Nakae S et al. (2007) Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J Leukoc Biol 81: 1258\u20131268","journal-title":"J Leukoc Biol"},{"key":"BFncprheum0987_CR88","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1038\/ng.175","volume":"40","author":"JC Barrett","year":"2008","unstructured":"Barrett JC et al. (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 40: 955\u2013962","journal-title":"Nat Genet"},{"key":"BFncprheum0987_CR89","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.4049\/jimmunol.169.6.2818","volume":"169","author":"MP Martin","year":"2002","unstructured":"Martin MP et al. (2002) Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. J Immunol 169: 2818\u20132822","journal-title":"J Immunol"},{"key":"BFncprheum0987_CR90","doi-asserted-by":"crossref","unstructured":"International HapMap Consortium (2005) A haplotype map of the human genome. Nature 437: 1299\u20131320","DOI":"10.1038\/nature04226"}],"container-title":["Nature Clinical Practice Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0987.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0987","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncprheum0987.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T10:16:05Z","timestamp":1738923365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncprheum0987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,2]]}},"alternative-id":["BFncprheum0987"],"URL":"https:\/\/doi.org\/10.1038\/ncprheum0987","relation":{},"ISSN":["1745-8382","1745-8390"],"issn-type":[{"value":"1745-8382","type":"print"},{"value":"1745-8390","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2]]}}}